Tag:

Nupathe

Latest Headlines

Latest Headlines

Endo bets up to $221M on NuPathe and its migraine patch

Endo Health Solutions is extending its makeover with a bolt-on deal, trading $105 million up front for NuPathe to get its hands on the migraine patch Zecuity.

NuPathe jumps on FDA's OK for migraine drug

NuPathe crossed the regulatory finish line with FDA approval of its migraine patch, Zecuity, overcoming the agency's concerns about the battery-powered delivery system that prompted a denial from U.S. regulators in 2011.

NuPathe slashes staff to complete $28M raise ahead of PDUFA date

Hunkering down ahead of a January 17 PDUFA date for its experimental migraine patch, NuPathe says it will lay off half of its staff as it conserves resources, raises cash and looks for a partner to help commercialize the product in the event of an approval.

NuPathe shares in meltdown after FDA rejects migraine patch app

The FDA has handed NuPathe a complete response letter detailing demands for new information on its experimental migraine patch, Zelrix (NP101). But even after scrambling to try and reassure investors

NuPathe's price cut shows slow biotech IPO recovery

Conshohocken, PA-based NuPathe has cuts its IPO price to just $10 a share, the company announced today. NuPathe was hoping to raise between $14 and $16 per share for a total of $75 million. The

NuPathe plans to raise $75M with IPO

Conshohocken, PA-based NuPathe, which is developing a transdermal patch version of the popular migraine treatment Imitrex, has set the terms of its proposed IPO. NuPathe will offer 5 million common

NuPathe plots $86M IPO

Yet another biotech company has announced plans to file an IPO. Conshohocken, PA-based NuPathe, which is developing a transdermal patch to treat migraines, hopes to raise $86.3 million, according to

NuPathe reports positive results for migraine patch

NuPathe announced positive results from a key late-stage study of Zelrix, a transdermal patch designed for the treatment of acute migraine. The multi-center trial involved 530 adults. Data from the